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Malignant hyperthermia is a rare but life-threatening complication of general anesthesia in predisposed patients usually triggered
by potent inhalation anesthetics and/or the depolarizing muscle relaxant succinylcholine. The authors present a case of delayed
sevoflurane-inducedmalignant hyperthermia in a 21-year-oldmale patient that was sufficiently treated by discontinuation of trigger
agent application and dantrolene infusion. After surviving an MH episode diagnostic procedures are indicated to increase patient
safety. In the presented case, the use of a novel minimal-invasive metabolic test with intramuscular injection of halothane and
caffeine successfully confirmed MH susceptibility and hence might be an alternative for invasive in vitro contracture testing in
selected cases.
1. Introduction
Malignant hyperthermia (MH) is a rare but potentially
lethal pharmacological induced disease of skeletal muscle.
Exposure to triggering agents such as volatile anesthetics
and/or the depolarizing muscle relaxant succinylcholine may
induce a hypermetabolic muscular syndrome characterized
by hypoxemia, hypercapnia, tachycardia, muscular rigidity,
acidosis, hyperkalemia, and hyperthermia, due to an uncon-
trolled sarcoplasmic calcium release via functionally altered
ryanodine receptors subtype 1 or dihydropyridine receptors
[1]. Currently, the in vitro contracture test (IVCT) requiring
an open muscle biopsy is the only reliable procedure to
diagnoseMHsusceptibility in affected patients.However, due
to its invasive characteristics this test is associated with severe
risks to the patients, for example, wound infections, postoper-
ative bleeding, or persistent dysesthesia. Important progress
was made within the last years by screening for causative
MH mutations, which allows a genetic diagnosis in 30% to
50% of MH families [2]. Unfortunately, a negative genetic
result does not sufficiently exclude MH susceptibility and
hence must be confirmed by IVCT [3]. Recently, a minimal-
invasive metabolic test was proposed to analyze muscular
alterations in MH patients under in vivo conditions. The
local monitoring of interstitial lactate concentrations after
pharmacological stimulation induced by MH trigger agents
allowed a differentiation betweenMH susceptible (MHS) and
MH nonsusceptible (MHN) patients [4].
In the presented case report, we used this minimal-inva-
sive test to screen for MH susceptibility in a patient who
developed clinical sings of MH during general anesthesia
with sevoflurane while undergoing an elective shoulder
arthroscopy.
2. Case Presentation
2.1. Intra- and Postoperative Course. With approval of the
local ethics committee (application number: 263/11, ethics
committee of the University of Wuerzburg), we report the
case of a 21-year-old male patient weighting 100 kg, who
was scheduled for elective shoulder arthroscopy. Neither the
patient nor his family had any history of neuromuscular
disease or MH. According to the medical records, the patient
underwent two uneventful anesthesias using halothane com-
bined with oxygen (O
2
) and nitrous oxide (N
2
O) for cleft
lip revision at the age of 5 months and at the age of 4
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years, respectively.The preoperative laboratory examinations
were within normal values. Initial heart rate (95 bpm), blood
pressure (145/80mmHg), and peripheral oxygen saturation
(96%) were unremarkable. Anesthesia was induced by intra-
venous application of 0.1mg/kg piritramid, an initial bolus of
2.5mg/kg propofol followed by an additional application of
1.5mg/kg propofol, and 1.5mg/kg succinylcholine. To secure
patient’s airways, a size 8,0mm cuffed endotracheal tube was
inserted after direct laryngoscopy. Afterwards, anesthesia was
maintained by sevoflurane 1.5 vol% supplemented byO
2
/N
2
O
and application of 0.05mg/kg piritramid if needed. During
the initial period of surgery, hemodynamic and metabolic
parameters were within normal limits with end-tidal carbon
dioxide values between 38 and 39mmHg. Suddenly, after
290min a slightly increase of heart rate from 60 bpm to
80 bpm and a rise in systolic blood pressure from 120mmHg
to 135mmHg were noticed. Furthermore, end-tidal carbon
dioxide concentration rapidly increased from 39mmHg to
85mmHg within 5min after the onset of sinus tachycardia.
Simultaneously, oxygen saturation decreased from 98% to
93%. Unfortunately, there was no monitoring of body tem-
perature, but the attending anesthesiologist observed and
documented warming of head and chest during this episode.
After MH was suspected, the anesthesiologist immediately
stopped sevoflurane and hyperventilated the patient with
100% oxygen (25 L/min). In addition, 240mg dantrolene was
applied twice and anesthesia was continued intravenously
by infusion of 5mg/kg/h propofol and repeated fentanyl
applications. After these interventions, hemodynamic and
metabolic parameters were stabilized within 10min.The sur-
gical procedure was stopped, and the patient was transferred
to the intensive care unit (ICU) in stable conditions.
Laboratory analyses performed after admission to the
ICU detected a significant rhabdomyolysis with crea-
tine kinase levels about 20.000U/L and a hyperkalemia
(6.4mmol/L). Further laboratory data were unremarkable.
Interestingly, blood gas analysis drawn one hour after the
MH suspected event did not show signs of metabolic or
respiratory acidosis. Four hours after the admission, the
patient was extubated without neurological deficits.
3. Diagnostic Findings
Due to the suspected MH event, the patient was informed
about the possible risk of MH susceptibility and a diagnostic
workup was recommended. Hence, after written and oral
informed consent of the patient, we decided to perform
the recently developed minimal-invasive metabolic test three
days after the suspected MH episode. In brief, after regional
anesthesia of the skin, two microdialysis probes with a
semipermeable membrane for measurement of interstitial
metabolites were inserted into the lateral vastus muscle
and perfused with 1 𝜇L/min Ringer’s solution. 15min after
equilibration either a single bolus of 200𝜇L halothane 4 vol%
dissolved in soy bean oil or 200𝜇L caffeine 80mM was
injected into the muscular tissue. Dialysate samples were
collected after 15-minute intervals, and lactate concentra-
tion was measured spectrophotometrically. If lactate values
exceeded a threshold of 2.8mM after halothane or 1.6mM
after caffeine, which had been defined by a previous set of
tests, MH susceptibility was assumed [4]. Prior to halothane
or caffeine application, the baseline lactate levels did not sig-
nificantly differ between both microdialysis probes (0.4mM
versus 0.8mM). After halothane injection the lactate values
significantly increased to a maximum of 3.7mM. Similarly,
caffeine induced a significant increase of lactate to 3.1mM
(Table 1).
Even though MH susceptibility had been confirmed by
this metabolic test, the patient decided to undergo further
diagnostic testing due to personal reasons. Due to the
MH suspected course of the described case and to avoid
invasive IVCT, we determined to screen the hotspots of the
ryanodine receptor subtype 1 gene forMH related alterations.
Unfortunately, genetic analysis did not detect MH associated
mutations. Hence, twelve weeks after theMH suspected event
an open muscle biopsy and IVCT according to published
guidelines of the European MH Group were performed at
our lab [3]. In few words, 2.5 g muscle tissue was excised of
the left vastus lateral muscle after femoral nerve block. Single
muscle bundles weremounted in a tissue bath and exposed to
incremental concentrations of caffeine (0.5; 1; 1.5; 2; 3; 4; and
32mM) or halothane (0.11; 0.22; 0.44; and 0.66mM) at 3min
intervals. Since significant contractures ≥ 2mN occurred at
the defined threshold concentrations of caffeine 2mM and
halothane 0.44mM, the MH-susceptibility of the patient was
confirmed (Table 2).
4. Discussion
Malignant hyperthermia is a rare but life-threatening com-
plication of general anesthesia usually triggered by volatile
anesthetics and/or succinylcholine in susceptible patients.
While genetic frequency of MH predisposition is stated to
be 1 : 2.000, the prevalence of MH-episodes varies regionally
between 1 : 10.000 and 1 : 220.000 [5].
Nowadays, due to continuous progress in anesthesia, it
seems that the incidence of fulminant MH crisis decreases.
Since the potent MH trigger halothane is no longer used
in clinical routine in industrialized countries, the presently
utilized inhalation anesthetics appear to delay the onset
of MH or lead to abortive MH reactions with alleviated
symptoms. For instance, Hopkins and colleagues reported
that the onset of MH was significantly faster after halothane
exposure (median: 20min, range: 5–45min) compared to
sevoflurane (median: 60min, range: 10–210min) [6]. Hence,
the intraoperative course in the presented case with devel-
opment of MH signs 290min after induction of general
anesthesia seems consistent with these findings. However, in
some cases application of sevoflurane inducesMH symptoms
within few minutes [7].
In addition, anesthesiologistsmust be aware that previous
uneventful anesthesia does not excludeMH susceptibility [8].
On average, susceptible patients undergo three uneventful
anesthesias until the first MH episode occurs [5]. In this
context, it is not surprising that the presented patient reported
two unremarkable anesthesias in the past. The underlying
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Table 1: Local lactate increase following interstitial application of 200𝜇L caffeine 80mM and 200 𝜇L halothane 4 vol%.
Time 0min 15min 30min 45min 60min 75min
Caffeine 80mM 0.4mM 0.6mM 0.7mM 2.7mM 3.1mM 2.7mM
Halothane 4 vol% 0.8mM 0.7mM 0.9mM 2.1mM 3.7mM 2.8mM
0min: baseline lactate levels; 15min: time point of caffeine or halothane injection.
Table 2: In vitro contracture test results. A contracture ≥ 2mN at the defined threshold concentrations of caffeine 2mM and halothane
0.44mM confirmed MH susceptibility.
Caffeine Predrug 0,5mM 1mM 1,5mM 2mM 3mM 4mM 32mM
Test 1 14.0mN 13.5mN 15.6mN 19.6mN 25.6mN 29.1mN 29.1mN 144mN
Test 2 12.7mN 12.2mN 13.0mN 17.8mN 24.7mN 35.7mN 32.2mN 209mN
Halothane Predrug 0,11mM 0,22mM 0,44mM 0,66mM
Test 1 11.6mN 23.0mN 35.1mN 32.1mN 26.5mN
Test 2 19.1mN 20.9mN 28.1mN 29.5mN 26.8mN
pathomechanism why some patients develop MH during
the first exposition to triggering agents while others do not
still remains unclear. A possible explanation might be the
presence of an individual compensation mechanism at a
cellular level loweringmyoplasmic calcium concentrations in
these patients.
Based on these observations, attending anesthesiologists
must keep in mind that MH may occur at any time during
general anesthesia and prior unremarkable anesthesias, are
not a prove for the absence of MH susceptibility.
In case of a suspected MH, application of trigger agents
must be discontinued immediately and causal therapy by
dantrolene infusion should be initiated to avoid serious harm
to the patient [9]. The mode of action of dantrolene is based
on inhibition of the sarcoplasmic calcium release during
an MH episode without increasing sarcoplasmic calcium
reuptake [10]. The return of metabolic parameters to normal
values reflects the therapeutic success of MH treatment,
comparable to the absent of metabolic or respiratory acidosis
in the presented case.
Due to the possible risk in case of future anesthesia,
patients should be referred to a MH-center to initiate further
diagnostics after surviving a suspected MH event. In the
reported case, the authors decided to apply a novel minimal-
invasive metabolic test with intramuscular halothane and
caffeine injection to screen for MH susceptibility. Based
on the metabolic alterations in the course of an MH
episode, measurement of interstitial lactate concentration
was assumed as a suitable method to detect MH in affected
patients. The measured increase of local lactate concentra-
tions following halothane and caffeine application clearly
indicated the diagnosis “MHS” in our patient. In contrast
to the IVCT, the metabolic test is less invasive; since the
induced metabolic reactions are limited to an area < 10mm
around the inserted microdialysis probes and due to the
expected dilutional effects of the administered drugs in the
tissue, serious systemic, or local adverse effects are unlikely
[11]. Furthermore, previous histological examination of rat
muscular tissue after application of caffeine 80mM revealed
only unspecific morphological changes [12].
AlthoughMH susceptibility was proven by the metabolic
test, the patient decided to undergo further diagnostic testing.
Due to the clinical course of the reported MH reaction and
in contrast to the diagnostic guidelines of the European
MH Group, we decided to perform genetic screening at
first. Unfortunately, no mutation of the ryanodine receptor
subtype 1 could be detected in the patient. Hence, IVCT was
carried out eight weeks after the suspicious event, since the
absence of a mutation does not reliably exclude MH [13].
In summary, the authors present a case of a delayed
sevoflurane-induced MH in a 21-year-old male patient, who
was sufficiently treated by dantrolene and discontinuation
of trigger agent application. After surviving an MH episode
diagnostic procedures are indicted to increase patient safety.
In the presented case, the use of a novel minimal-invasive
metabolic test with intramuscular application of MH trigger-
ing agents such as halothane and caffeine successfully proved
MH susceptibility and hence might avoid invasive in vitro
contracture testing in selected cases.
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